<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - OMALIZUMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>OMALIZUMAB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of severe persistent allergic asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Dose according to immunoglobulin E concentration and body-weight (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H<sub>1</sub> antihistamine treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg every 4 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless essential&#8212;crosses the placenta.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises caution&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution&#8212;no information available.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, arthralgia, headache, injection-site reactions, pyrexia, sinusitis, upper respiratory tract infection,
              </p>
              <p>
                <strong>uncommon:</strong> Bronchospasm, cough, diarrhoea, dizziness, drowsiness, dyspepsia, flushing, influenza-like illness, malaise, nausea, paraesthesia, pharyngitis, photosensitivity, postural hypotension, pruritus, rash, syncope, urticaria, weight gain,
              </p>
              <p>
                <strong>rare:</strong> Angioedema, antibody formation, laryngoedema, parasitic infection,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, arterial thromboembolic events, Churg-Strauss syndrome, joint swelling, myalgia, serum sickness (including fever and lymphadenopathy), thrombocytopenia,
              </p>
        
        
            <section class="advice">
                <h3>Churg-Strauss syndrome</h3>
              <p>Churg-Strauss syndrome has occurred rarely in patients given omalizumab; the reaction is usually associated with the reduction of oral corticosteroid therapy. Churg-Strauss syndrome can present as eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, or peripheral neuropathy.</p>
            </section>
            <section class="advice">
                <h3>Hypersensitivity reactions</h3>
              <p>Hypersensitivity reactions can also occur immediately following treatment with omalizumab or sometimes more than 24 hours after the first injection.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE</h3>
              <p outputclass="title">Omalizumab for previously treated chronic spontaneous urticaria (June 2015)</p> <p>Omalizumab is an option as add-on therapy for the treatment of severe chronic spontaneous urticaria in patients 12 years and over, only if:</p> <ul> <li>the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more,</li> <li>the patient's condition has not responded to standard treatment with H<sub>1</sub>-antihistamines and leukotriene receptor antagonists,</li> <li>omalizumab is stopped at or before the fourth dose if the condition has not responded,</li> <li>omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded and is restarted only if the condition relapses,</li> <li>omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy,</li> <li>the manufacturer provides omalizumab with the discount agreed in the patient access scheme.</li> </ul> <p>Patients currently receiving omalizumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="https://www.nice.org.uk/TA339">www.nice.org.uk/TA339</xref>
                <a href="https://www.nice.org.uk/TA339" target="_blank">www.nice.org.uk/TA339</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA278</h3>
              <p outputclass="title">Omalizumab for severe persistent allergic asthma (April 2013)</p> <p>Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard therapy in patients aged 6 years and over:</p> <ul> <li>who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year), <b>and</b> </li> <li>only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme.</li> </ul> <p>Optimised standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta<sub>2</sub> agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.</p> <p>Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA278">www.nice.org.uk/TA278</xref>
                <a href="http://www.nice.org.uk/TA278" target="_blank">www.nice.org.uk/TA278</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Autoimmune disease
          </li>
          <li>
            susceptibility to helminth infection&#8212;discontinue if infection does not respond to anthelmintic
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of OMALIZUMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75747"><a href="../medicinalForm/PHP75747.html" data-target="#PHP75747" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
